NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$0.78
+0.03 (+3.42%)
Financial Highlights (FY 2025)
Revenue
1.58M
Net Income
134.3K
Gross Margin
48.8%
Profit Margin
8.5%
Rev Growth
+15.5%
D/E Ratio
0.19
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 48.8% | 48.8% | 48.8% |
| Operating Margin | 12.7% | 11.2% | 12.0% |
| Profit Margin | 8.5% | 10.1% | 10.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Gross Profit | 773.3K | 789.7K | 623.6K |
| Operating Income | 200.8K | 181.5K | 153.7K |
| Net Income | 134.3K | 163.7K | 131.8K |
| Gross Margin | 48.8% | 48.8% | 48.8% |
| Operating Margin | 12.7% | 11.2% | 12.0% |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| Rev Growth | +15.5% | +19.0% | +13.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.76M | 1.65M | 1.88M |
| Total Equity | 9.24M | 9.14M | 9.98M |
| D/E Ratio | 0.19 | 0.18 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |